MARKET

VYNE

VYNE

Vyne Therapeutics Inc
NASDAQ
0.5616
-0.0264
-4.49%
After Hours: 0.5551 -0.0065 -1.16% 17:44 12/29 EST
OPEN
0.5730
PREV CLOSE
0.5880
HIGH
0.5826
LOW
0.5515
VOLUME
1.49M
TURNOVER
--
52 WEEK HIGH
4.300
52 WEEK LOW
0.2805
MARKET CAP
18.69M
P/E (TTM)
-0.7120
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VYNE last week (1222-1226)?
Weekly Report · 20h ago
Weekly Report: what happened at VYNE last week (1215-1219)?
Weekly Report · 12/22 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/18 21:05
3 Penny Stocks to Watch Now, 12/18/25
TipRanks · 12/18 14:25
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
PR Newswire · 12/17 21:35
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 12/17 17:06
VYNE Therapeutics to merge With Yarrow Bioscience, secures $200M financing; shares up
Seeking Alpha · 12/17 16:18
Hold Rating for VYNE Therapeutics Amid Strategic Shift and Clinical Uncertainty Following Yarrow Bioscience Merger
TipRanks · 12/17 16:05
More
About VYNE
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Webull offers Vyne Therapeutics Inc stock information, including NASDAQ: VYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYNE stock methods without spending real money on the virtual paper trading platform.